CAS 652153-01-0
:Zanolimumab
Description:
Zanolimumab, with the CAS number 652153-01-0, is a monoclonal antibody that primarily targets the CD4 receptor on T cells. It is designed to modulate immune responses, making it a candidate for therapeutic applications in autoimmune diseases and certain types of cancer. As a humanized IgG1 antibody, Zanolimumab exhibits high specificity and affinity for its target, which helps in reducing the risk of immunogenicity compared to fully murine antibodies. The mechanism of action involves blocking the interaction between CD4 and MHC class II molecules, thereby inhibiting T cell activation and proliferation. This characteristic makes it a potential treatment option for conditions characterized by excessive T cell activity. Zanolimumab has undergone various clinical trials to evaluate its efficacy and safety profile, particularly in the context of diseases such as rheumatoid arthritis and psoriasis. Its development reflects ongoing efforts in biopharmaceuticals to harness the immune system for therapeutic benefit while minimizing adverse effects.
Formula:Unspecified
Synonyms:- HuMax CD 4
- MDX 016
- Immunoglobulin, anti-(human CD4 (antigen)) (human monoclonal 6G5 heavy chain), disulfide with human monoclonal 6G5 light chain, dimer
- Zanolimumab
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
Zanolimumab
CAS:Zanolimumab is a humanised monoclonal antibody targeting CD4, blocking TCR signalling, autoimmune diseases such as rheumatoid arthritisa.Purity:95%Color and Shape:LiquidMolecular weight:143.81 kDa
